Latest revenue
$336.6M
as of 2026-03-31
Latest net income
$13.3M
as of 2026-03-31
Net margin
3.9%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Retail-Drug Stores and Proprietary Stores (5 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think GRDN is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- —
- Enterprise value
- —
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- 52-wk high
- —
- 52-wk low
- —
- Beta
- —
- Shares out
- —
5-year trend
What this company does
Item 1. Business. Overview We are a leading, highly differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. We emphasize high-touch, individualized clinical, drug dispensing and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as assisted living facilities (“ALFs”), and behavioral health facilities and group homes (collectively “BHFs”). More than two-thirds of our annual revenue for each of the past three years has been…
AI summary unavailable — showing raw filing excerpt
Generated from GRDN's filing dated 2026-03-11
Key risks
Item 1A. Risk Factors. Investing in our Class A common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K and the other documents that we file with the SEC from time to time, including our consolidated financial statements and related notes, before deciding whether to invest in our Class A common stock. Any of the following risks could materially and adversely affect our business, financial condition, results of operations and prospects. In that event, the market price of our Class A common stock could decline, and you could lose part or all of your…
AI summary unavailable — showing raw filing excerpt
Generated from GRDN's filing dated 2026-03-11
Profitability
Gross margin
20.2%
1.6%Operating margin
5.0%
198.0%Net margin
3.4%
137.9%Return on assets
11.9%
134.8%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $336.6M | +2.2% | $13.3M | +40.7% | 3.9% |
Q4 2025 2025-12-31 | $397.6M | +17.4% | $20.9M | +331.6% | 5.3% |
Q3 2025 2025-09-30 | $377.4M | +20.0% | $9.8M | +108.0% | 2.6% |
Q2 2025 2025-06-30 | $344.3M | +14.8% | $9.0M | — | 2.6% |
Q1 2025 2025-03-31 | $329.3M | +19.6% | $9.4M | +33.2% | 2.9% |
Q4 2024 2024-12-31 | $338.6M | — | $4.8M | — | 1.4% |
Q3 2024 2024-09-30 | $314.4M | — | $-122.0M | — | -38.8% |
Q2 2024 2024-06-30 | $300.0M | — | $0 | — | 0.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Retail-Drug Stores and Proprietary Stores · SIC 5912
Your notes
Keep private notes on GRDN — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$99.8K
Insider selling
$419.3M
Net activity
−$419.2M
Distinct insiders
10
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns GRDN
Institutional value
$403.1M
Total shares held
11.0M
Distinct holders
89
-39 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1.8M | $66.1M | +13.5K (+0.8%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $46.2M | — | New |
| 3 | TimesSquare Capital Management, LLC | 1.1M | $40.6M | +29.3K (+2.8%) | Added |
| 4 | Boston Partners | 1.0M | $38.4M | -37.0K (-3.5%) | Trimmed |
| 5 | FRANKLIN RESOURCES INC | 953.0K | $35.9M | -38.4K (-3.9%) | Trimmed |
| 6 | JENNISON ASSOCIATES LLC | 822.8K | $31.0M | +706.8K (+609.5%) | Added |
| 7 | Nuveen, LLC | 537.5K | $20.2M | -104.9K (-16.3%) | Trimmed |
| 8 | SEI INVESTMENTS CO | 358.2K | $13.5M | +103.2K (+40.5%) | Added |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 248.5K | $9.4M | — | New |
| 10 | DIMENSIONAL FUND ADVISORS LP | 208.6K | $7.9M | +139.1K (+200.0%) | Added |
| 11 | Clearbridge Investments, LLC | 202.8K | $7.6M | -6.5K (-3.1%) | Trimmed |
| 12 | PEREGRINE CAPITAL MANAGEMENT LLC | 201.6K | $7.6M | -19.5K (-8.8%) | Trimmed |
| 13 | SEVEN GRAND MANAGERS, LLC | 200.0K | $7.5M | +100.0K (+100.0%) | Added |
| 14 | Lisanti Capital Growth, LLC | 188.2K | $7.1M | — | New |
| 15 | VANGUARD FIDUCIARY TRUST CO | 173.2K | $6.5M | — | New |
| 16 | Hudson Bay Capital Management LP | 141.8K | $5.3M | — | New |
| 17 | Allspring Global Investments Holdings, LLC | 136.0K | $5.1M | -7.6K (-5.3%) | Trimmed |
| 18 | JANE STREET GROUP, LLC | 115.6K | $4.4M | — | New |
| 19 | Russell Investments Group, Ltd. | 105.4K | $4.0M | +14.4K (+15.8%) | Added |
| 20 | FIRST TRUST ADVISORS LP | 93.7K | $3.5M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once GRDN's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.